- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ISG Technologies changes name
PACS and image-guided surgery firm ISG Technologies has changed its name. Now called Cedara Software, the Mississauga, ON-based firm has embarked on a worldwide corporate branding campaign intended to highlight the company’s healthcare software
PACS and image-guided surgery firm ISG Technologies has changed its name. Now called Cedara Software, the Mississauga, ON-based firm has embarked on a worldwide corporate branding campaign intended to highlight the companys healthcare software products and services. The name change and the companys new stock trading symbols are contingent on shareholder approval. Until they receive approval, the firm will continue to trade under ISO (Toronto Stock Exchange) and ISGTF (Nasdaq).
Cedara will be divided into three core businesses: software and service, image management, and image-guided therapy. Two of the three businesses have gained new executive leadership in the past year. The company named Arun Menawat to the post of general manager/president of the software and service division, which develops the companys Image Application Platform software, designed for 3-D post-processing, CT, digital x-ray, MRI, mammography, nuclear medicine, and ultrasound equipment. Cedara has also appointed Alyn Ford to the position of general manager/vice president of its image management business, which develops software products that display, analyze, and store medical images.
In other ISG/Cedara news, the company posted healthy revenues and earnings for fiscal year 1999 (end-June). ISG saw revenues of $47 million, up 30% from $36.1 million the previous year. Earnings were $1.8 million, compared with $498,000 in 1998.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
